Physiologically Based Pharmacokinetic Modeling of Cannabidiol, Delta‐9‐Tetrahydrocannabinol, and Their Metabolites in Healthy Adults After Administration by Multiple Routes

ABSTRACT The two most extensively studied cannabinoids, cannabidiol (CBD) and delta‐9‐tetrahydrocannabinol (THC), are used for myriad conditions. THC is predominantly eliminated via the cytochromes P450 (CYPs), whereas CBD is eliminated through both CYPs and UDP‐glucuronosyltransferases (UGTs). The...

Full description

Saved in:
Bibliographic Details
Main Authors: Lixuan Qian, Tao Zhang, Jean Dinh, Mary F. Paine, Zhu Zhou
Format: Article
Language:English
Published: Wiley 2025-01-01
Series:Clinical and Translational Science
Subjects:
Online Access:https://doi.org/10.1111/cts.70119
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832589760618561536
author Lixuan Qian
Tao Zhang
Jean Dinh
Mary F. Paine
Zhu Zhou
author_facet Lixuan Qian
Tao Zhang
Jean Dinh
Mary F. Paine
Zhu Zhou
author_sort Lixuan Qian
collection DOAJ
description ABSTRACT The two most extensively studied cannabinoids, cannabidiol (CBD) and delta‐9‐tetrahydrocannabinol (THC), are used for myriad conditions. THC is predominantly eliminated via the cytochromes P450 (CYPs), whereas CBD is eliminated through both CYPs and UDP‐glucuronosyltransferases (UGTs). The fractional contributions of these enzymes to cannabinoid metabolism have shown conflicting results among studies. Physiologically based pharmacokinetic (PBPK) models for CBD and THC and for drug–drug interaction studies involving CBD or THC as object drugs were developed and verified to improve estimates of these contributions. First, physicochemical and pharmacokinetic parameters for CBD, THC, and their metabolites (7‐OH‐CBD, 11‐OH‐THC, and 11‐COOH‐THC) were obtained from the literature or optimized. Second, PBPK base models were developed for CBD and THC after intravenous administration. Third, beginning with the intravenous models, absorption models were developed for CBD after oral and oromucosal spray administration and for THC after oral, inhalation, and oromucosal spray administration. The full models well‐captured the area under the concentration–time curve (AUC) and peak concentration (Cmax) of CBD and THC from the verification dataset. Predicted AUC and Cmax for CBD and 7‐OH‐CBD were within two‐fold of the observed data. For THC, 11‐OH‐THC, and 11‐COOH‐THC, 100%, 100%, and 83% of the predicted AUC values were within two‐fold, respectively, of the observed values; 100%, 92%, and 94% of the predicted Cmax values, respectively, were within two‐fold of the observed values. The verified models could be used to help address critical public health needs, including assessing potential drug interaction risks involving CBD and THC.
format Article
id doaj-art-477211d0eb16408d9294d2e2a3667024
institution Kabale University
issn 1752-8054
1752-8062
language English
publishDate 2025-01-01
publisher Wiley
record_format Article
series Clinical and Translational Science
spelling doaj-art-477211d0eb16408d9294d2e2a36670242025-01-24T08:17:46ZengWileyClinical and Translational Science1752-80541752-80622025-01-01181n/an/a10.1111/cts.70119Physiologically Based Pharmacokinetic Modeling of Cannabidiol, Delta‐9‐Tetrahydrocannabinol, and Their Metabolites in Healthy Adults After Administration by Multiple RoutesLixuan Qian0Tao Zhang1Jean Dinh2Mary F. Paine3Zhu Zhou4Department of Chemistry York College, City University of New York New York USADepartment of Pharmaceutical Sciences Binghamton University, the State University of New York Vestal New York USASimCYP Ltd/Certara Sheffield UKDepartment of Pharmaceutical Sciences Washington State University Pullman Washington USADepartment of Chemistry York College, City University of New York New York USAABSTRACT The two most extensively studied cannabinoids, cannabidiol (CBD) and delta‐9‐tetrahydrocannabinol (THC), are used for myriad conditions. THC is predominantly eliminated via the cytochromes P450 (CYPs), whereas CBD is eliminated through both CYPs and UDP‐glucuronosyltransferases (UGTs). The fractional contributions of these enzymes to cannabinoid metabolism have shown conflicting results among studies. Physiologically based pharmacokinetic (PBPK) models for CBD and THC and for drug–drug interaction studies involving CBD or THC as object drugs were developed and verified to improve estimates of these contributions. First, physicochemical and pharmacokinetic parameters for CBD, THC, and their metabolites (7‐OH‐CBD, 11‐OH‐THC, and 11‐COOH‐THC) were obtained from the literature or optimized. Second, PBPK base models were developed for CBD and THC after intravenous administration. Third, beginning with the intravenous models, absorption models were developed for CBD after oral and oromucosal spray administration and for THC after oral, inhalation, and oromucosal spray administration. The full models well‐captured the area under the concentration–time curve (AUC) and peak concentration (Cmax) of CBD and THC from the verification dataset. Predicted AUC and Cmax for CBD and 7‐OH‐CBD were within two‐fold of the observed data. For THC, 11‐OH‐THC, and 11‐COOH‐THC, 100%, 100%, and 83% of the predicted AUC values were within two‐fold, respectively, of the observed values; 100%, 92%, and 94% of the predicted Cmax values, respectively, were within two‐fold of the observed values. The verified models could be used to help address critical public health needs, including assessing potential drug interaction risks involving CBD and THC.https://doi.org/10.1111/cts.70119cannabidiolcannabinoidsdelta‐9‐tetrahydrocannabinolmetabolitesPBPKpharmacokinetics
spellingShingle Lixuan Qian
Tao Zhang
Jean Dinh
Mary F. Paine
Zhu Zhou
Physiologically Based Pharmacokinetic Modeling of Cannabidiol, Delta‐9‐Tetrahydrocannabinol, and Their Metabolites in Healthy Adults After Administration by Multiple Routes
Clinical and Translational Science
cannabidiol
cannabinoids
delta‐9‐tetrahydrocannabinol
metabolites
PBPK
pharmacokinetics
title Physiologically Based Pharmacokinetic Modeling of Cannabidiol, Delta‐9‐Tetrahydrocannabinol, and Their Metabolites in Healthy Adults After Administration by Multiple Routes
title_full Physiologically Based Pharmacokinetic Modeling of Cannabidiol, Delta‐9‐Tetrahydrocannabinol, and Their Metabolites in Healthy Adults After Administration by Multiple Routes
title_fullStr Physiologically Based Pharmacokinetic Modeling of Cannabidiol, Delta‐9‐Tetrahydrocannabinol, and Their Metabolites in Healthy Adults After Administration by Multiple Routes
title_full_unstemmed Physiologically Based Pharmacokinetic Modeling of Cannabidiol, Delta‐9‐Tetrahydrocannabinol, and Their Metabolites in Healthy Adults After Administration by Multiple Routes
title_short Physiologically Based Pharmacokinetic Modeling of Cannabidiol, Delta‐9‐Tetrahydrocannabinol, and Their Metabolites in Healthy Adults After Administration by Multiple Routes
title_sort physiologically based pharmacokinetic modeling of cannabidiol delta 9 tetrahydrocannabinol and their metabolites in healthy adults after administration by multiple routes
topic cannabidiol
cannabinoids
delta‐9‐tetrahydrocannabinol
metabolites
PBPK
pharmacokinetics
url https://doi.org/10.1111/cts.70119
work_keys_str_mv AT lixuanqian physiologicallybasedpharmacokineticmodelingofcannabidioldelta9tetrahydrocannabinolandtheirmetabolitesinhealthyadultsafteradministrationbymultipleroutes
AT taozhang physiologicallybasedpharmacokineticmodelingofcannabidioldelta9tetrahydrocannabinolandtheirmetabolitesinhealthyadultsafteradministrationbymultipleroutes
AT jeandinh physiologicallybasedpharmacokineticmodelingofcannabidioldelta9tetrahydrocannabinolandtheirmetabolitesinhealthyadultsafteradministrationbymultipleroutes
AT maryfpaine physiologicallybasedpharmacokineticmodelingofcannabidioldelta9tetrahydrocannabinolandtheirmetabolitesinhealthyadultsafteradministrationbymultipleroutes
AT zhuzhou physiologicallybasedpharmacokineticmodelingofcannabidioldelta9tetrahydrocannabinolandtheirmetabolitesinhealthyadultsafteradministrationbymultipleroutes